Últimas noticias sobre Valhi (NYSE:VHI) Bolsa

Valhi

Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.

Valhi Inc

VITALHUB CORP COM NO PAR by VITALHUB CORP

Vitalhub Corp

<h3>Companies Reporting Before The Bell</h3>
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.40 per share on revenue of $154.43 million. 
• Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) is projected to report quarterly loss at $1.40 per share on revenue of $2.90 million. 
• PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is projected to report earnings for its fourth quarter. 
• FitLife Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTLF#NASDAQ">FTLF</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $14.95 million. 
• ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) is expected to report quarterly loss at $0.35 per share on revenue of $19.67 million. 
• Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is expected to report earnings for its fourth quarter. 
• Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is expected to report earnings for its fourth quarter. 
• Bitfarms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $53.82 million. 
• Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $608.95 million. 
• BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $16.80 million. 
• Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $20.83 million. 
• TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $8.24 million. 
• BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $2.29 million. 
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is expected to report quarterly loss at $0.07 per share on revenue of $1.07 million. 
• Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is likely to report earnings for its fourth quarter. 
• Ascentage Pharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) is projected to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONEK#NASDAQ">UONEK</a>) is estimated to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONE#NASDAQ">UONE</a>) is projected to report earnings for its fourth quarter. 
• TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.91 per share on revenue of $14.79 billion. 
• Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) is projected to report quarterly loss at $0.46 per share on revenue of $14.49 million. 
• Ermenegildo Zegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZGN#NYSE">ZGN</a>) is likely to report earnings for its Fiscal Year 2024. 
• Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) is projected to report earnings for its Fiscal Year 2024. 
<h3>Companies Reporting After The Bell</h3>
• Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $13.52 million. 
• Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) is projected to report earnings for its fourth quarter. 
• Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is projected to report quarterly loss at $0.66 per share on revenue of $1.45 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.85 million. 
• SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) is likely to report earnings for its fourth quarter. 
• INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is projected to report earnings for its fourth quarter. 
• TMC Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) is estimated to report earnings for its fourth quarter. 
• Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is expected to report quarterly loss at $0.40 per share on revenue of $9.03 million. 
• IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) is expected to report quarterly loss at $0.08 per share on revenue of $13.00 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is expected to report earnings for its fourth quarter. 
• TSS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) is expected to report earnings for its fourth quarter. 
• BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) is likely to report quarterly loss at $0.27 per share on revenue of $475 thousand. 
• Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly loss at $0.67 per share on revenue of $12.31 million. 
• Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) is expected to report earnings for its fourth quarter. 
• 374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) is likely to report quarterly loss at $0.02 per share on revenue of $100 thousand. 
• Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) is estimated to report earnings for its fourth quarter. 
• Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is projected to report quarterly loss at $0.95 per share on revenue of $920 thousand. 
• Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) is likely to report earnings for its fourth quarter. 
• BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter. 
• Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $0.51 per share on revenue of $1.19 million. 
• VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $8.09 million. 
• Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.37 million. 
• Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is likely to report quarterly loss at $0.31 per share on revenue of $6.20 million. 
• Beachbody Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) is likely to report quarterly loss at $1.52 per share on revenue of $81.71 million. 
• Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) is expected to report earnings for its fourth quarter. 
• Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $19.48 million. 
• Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $81.13 million. 
• Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is projected to report quarterly loss at $0.05 per share on revenue of $12.80 million. 
• AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $679.95 million. 
• Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $383.94 million. 
• P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.17 per share on revenue of $385.80 million. 
• Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) is likely to report quarterly loss at $0.34 per share on revenue of $375 thousand. 
• Argan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $212.05 million. 
• HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $9.30 million. 
• Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is expected to report quarterly earnings at $5.65 per share on revenue of $3.52 billion. 
• Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is likely to report quarterly loss at $0.11 per share on revenue of $294 thousand. 
• KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $2.87 million. 
• Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) is expected to report earnings for its fourth quarter. 
• Sky Harbour Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) is expected to report quarterly loss at $0.06 per share on revenue of $4.15 million. 
• Better Choice Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#AMEX">BTTR</a>) is likely to report earnings for its fourth quarter. 
• Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter. 
• Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $155.25 million. 
• Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is likely to report quarterly loss at $0.14 per share on revenue of $68.43 million. 
• Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is expected to report quarterly loss at $0.14 per share on revenue of $6.83 million. 
• Barfresh Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.17 million. 
• Abacus Global Management (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $30.18 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

AAPG

ABOS

ADCT

BCAB

BITF

BKTI

BKYI

The Beachbody Company, Inc. Class A Common Stock

BODI

BRFH

BRTX

BRZE

BTTR

BZAI

CLSD

CODX

DLPN

DPRO

DRCT

EDAP

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

FORA

FTLF

GEVO

GOVX

ICCM

INMB

IPHA

IRIX

IZEA

JFIN

KULR

LTRN

LULU

LVLU

MDAI

NUTX

PDSB

PIII

PLSE

PSTV

RLMD

SACH

SCWO

SDST

SKYH

SPRO

SSKN

TLSI

TSAT

TSSI

UMAC

UONE

UONEK

VTSI

WKSP

Earnings Scheduled For March 27, 2025

Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) will release its quarterly earnings report on Thursday, 2025-03-06. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Valhi to report an earnings per share (EPS) of $0.60.
Anticipation surrounds Valhi's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $1.41, leading to a 6.86% increase in the share price the following trading session.
Here's a look at Valhi's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.6</td>
<td>0.60</td>
<td>0.29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.8</td>
<td>2.01</td>
<td>0.70</td>
<td>0.27</td>
<td>0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>7.000000000000001%</td>
<td>12.0%</td>
<td>1.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<h3>Valhi Share Price Analysis</h3>
Shares of Valhi were trading at $17.36 as of March 25. Over the last 52-week period, shares are up 3.96%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/VHI/earnings">To track all earnings releases for Valhi visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Valhi's Earnings Forecast

Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.60 by 33.33 percent. This is a 370.59 percent increase over earnings of $0.17 per share from the same period last year. The company reported $480.90 million in sales this quarter. This is a 6.16 percent increase over sales of $453.00 million the same period last year.

Earnings Beats

News

Valhi Q4 EPS $0.80 Beats $0.60 Estimate, Sales $480.90M Up From $453.00M YoY

WIIM

ASPI

BSLK

CRKN

CRML

CTVA

FEAM

MATV

MEOH

NITO

SCCO

TROX

Shares of companies in the broader materials sector are trading lower amid overall market uncertainty after President Trump confirmed March 4 tariffs.

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.
Shares of Limoneira Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) fell sharply in today's pre-market trading after reporting <a href="https://www.benzinga.com/quote/LMNR/news">fourth-quarter results.</a>
Limoneira posted an adjusted net loss of $1.6 million, or 9 cents per share, versus a year-ago loss of $2.6 million, or 15 cents per share. Its total net revenue rose to $43.9 million from $41.4 million in the year-ago quarter.
Limoneira shares fell 2.6% to $26.12 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Tutor Perini Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) dipped 12.1% to $22.01 in pre-market trading.</li>
<li>Astria Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) fell 11.8% to $8.40 in pre-market trading.</li>
<li>Jiayin Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) shares fell 7.5% to $5.95 in pre-market trading. Jiayin Group, last week, announced the purchase of commercial property located in Shanghai, China for total cash consideration of RMB1.35 billion.</li>
<li>AngioDynamics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) dipped 7.3% to $8.21 in pre-market trading. AngioDynamics will report financial results for the second quarter of fiscal year before the opening bell on Wednesday, Jan. 8, 2025.</li>
<li>Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) fell 5.2% to $20.51 in pre-market trading.</li>
<li>ADS-TEC Energy PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSE#NASDAQ">ADSE</a>) shares fell 3% to $13.70 in pre-market trading.</li>
<li>Vinci Partners Investments Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) fell 2.9% to $9.57 in pre-market trading.</li>
<li>Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) declined 2.4% to $14.91 in pre-market trading.</li>
<li>Turtle Beach Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEAR#NASDAQ">HEAR</a>) declined 2.3% to $15.60 in pre-market trading.</li>
<li>Valhi, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) fell 2% to $21.30 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADSE

ANGO

ATXS

BASE

HEAR

LMNR

PAHC

VINP

Limoneira And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

LMFA

LOAR

LQDA

LUCD

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) is preparing to release its quarterly earnings on Thursday, 2024-11-07. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Valhi to report an earnings per share (EPS) of $0.60.
Valhi bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $0.41, leading to a 12.36% increase in the share price the following trading session.
Here's a look at Valhi's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.60</td>
<td>0.29</td>
<td></td>
<td></td>
<td>0.01</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.01</td>
<td>0.70</td>
<td>0.27</td>
<td>0.14</td>
<td>-0.21</td>
</tr>
<tr>
<td>Price Change %</td>
<td>7.000000000000001%</td>
<td>12.0%</td>
<td>1.0%</td>
<td>7.000000000000001%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<h3>Performance of Valhi Shares</h3>
Shares of Valhi were trading at $31.47 as of November 11. Over the last 52-week period, shares are up 120.93%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Valhi</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Valhi.
With 1 analyst ratings, Valhi has a consensus rating of Underperform. The average one-year price target is $20.0, indicating a potential 36.45% downside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Ecovyst, Rayonier Adv Materials and Ginkgo Bioworks Holdings, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Ecovyst is maintaining an Buy status according to analysts, with an average 1-year price target of $10.5, indicating a potential 66.63% downside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Rayonier Adv Materials, with an average 1-year price target of $11.0, indicating a potential 65.05% downside.</li>
<li>As per analysts' assessments, Ginkgo Bioworks Holdings is favoring an Buy trajectory, with an average 1-year price target of $8.5, suggesting a potential 72.99% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
In the peer analysis summary, key metrics for Ecovyst, Rayonier Adv Materials and Ginkgo Bioworks Holdings are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valhi</td>
<td>Underperform</td>
<td>10.37%</td>
<td>$121.30M</td>
<td>2.10%</td>
</tr>
<tr>
<td>Ecovyst</td>
<td>Buy</td>
<td>3.37%</td>
<td>$54.70M</td>
<td>1.97%</td>
</tr>
<tr>
<td>Rayonier Adv Materials</td>
<td>Outperform</td>
<td>8.80%</td>
<td>$43.57M</td>
<td>-4.38%</td>
</tr>
<tr>
<td>Ginkgo Bioworks Holdings</td>
<td>Buy</td>
<td>-30.24%</td>
<td>$42.48M</td>
<td>-23.88%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Valhi ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. Valhi is at the bottom for Return on Equity.
<h3>Unveiling the Story Behind Valhi</h3>
Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment. Chemicals Segment is a producer and marketer of value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to a wide variety of products, including paints, plastics, paper, fibers, and ceramics. Geographically the company operates in the United States, Germany, Canada, Norway, and Belgium, where the majority of revenue comes from the United States.
<h3>Unraveling the Financial Story of Valhi</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Valhi displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 10.37%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.56%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Valhi's ROE excels beyond industry benchmarks, reaching 2.1%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.78%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.54, Valhi adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/VHI/earnings">To track all earnings releases for Valhi visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Valhi

Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) reported quarterly earnings of $2.01 per share. The company reported $533.600 million in sales this quarter. This is a 13.80 percent increase over sales of $468.900 million the same period last year.

Valhi Q3 2024 GAAP EPS $2.01, Sales $533.600M Up From $468.900M YoY

Valhi shares are trading higher. Barclays raised its price target on the stock from $11 to $20.

Barclays analyst Michael Leithead maintains Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) with a Underweight and raises the price target from $11 to $20.

Price Target

Analyst Ratings

Barclays Maintains Underweight on Valhi, Raises Price Target to $20

U.S. stocks were higher, with the Dow Jones index falling around 300 points on Friday.
Shares of CAVA Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) rose sharply during Friday&#8217;s session as the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/08/40527721/these-analysts-increase-their-forecasts-on-cava-group-after-strong-earnings">second-quarter financial results on Thursday.</a>
Cava Group reported quarterly earnings of 17 cents per share which beat the analyst consensus estimate of 12 cents by 41.67%. Quarterly sales clocked in at $233.495 million, beating the analyst consensus estimate by 7% and representing a 35.05% increase from the same period last year.
CAVA Group jumped 17% to $119.37 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Graphjet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares jumped 18.8% to $3.1016.</li>
<li>Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) surged 18.3% to $9.84.</li>
<li>Lindblad Expeditions Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) gained 17.2% to $10.40.</li>
<li>Valhi, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) gained 13.2% to $27.66.</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) rose 12.5% to $14.57 after Barclays upgraded the stock from Equal-Weight to Overweight and raised its price target from $14 to $19.</li>
<li>Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) gained 10.6% to $255.66 as the company upbeat earnings for the second quarter.</li>
<li>NexGen Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) rose 10.1% to $6.39.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) gained 9% to $67.35. Guggenheim analyst Michael Morris upgraded Roku from Neutral to Buy.</li>
<li>BW LPG Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWLP#NYSE">BWLP</a>) rose 7.5% to $16.73.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) climbed 7.3% to $6.48.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) rose 6.4% to $36.37.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) gained 6% to $188.75.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40527921/top-wall-street-forecasters-revamp-trip-com-group-price-expectations-ahead-of-q2-earnings">Top Wall Street Forecasters Revamp Trip.com Group Price Expectations Ahead Of Q2 Earnings</a></li>
</ul>

Intraday Update

ARQT

ASTS

BILI

BWLP

CAVA

LIND

LUMN

Nuveen Arizona Dividend Advantage Municipal Funds 3

POWL

ROKU

WDAY

CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday

Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) reported $507.10 million in sales this quarter. This is the same as the same period last year.

Valhi Q2 Sales $507.10M, Same YoY

Comments

Valhi

Noticias

Últimas noticias sobre Valhi (NYSE:VHI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL